Heart Failure
Conditions
Interventions
Observation group:Participants who were prescribed with Naive Sacubitril/valsartan
Control group:Participants who were prescribed Sacubitril/valsartan transfered from ACEi/ARB
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Heart failure patients = 18 years old hospitalized in West China Hospital of Sichuan University from July 2020 to March 2022; 2. The diagnosis of heart failure complies with the diagnostic criteria of the 2018 Chinese Guidelines for the Diagnosis and Treatment of Heart Failure; 3. Use ACEI/ARB or ARNI drugs during hospitalization (at least 3 days before discharge); 4. At least one of the following outcome indicators can be obtained during the follow-up period of 3 months after discharge: patient's survival status, admission due to heart failure, cardiac function, cardiac function (NT proBNP), blood pressure, renal function (glomerular filtration rate) and electrolyte (blood potassium concentration).
Exclusion criteria
Exclusion criteria: 1. Patients taking blood pressure raising drugs at the same time; 2. Patients with contraindications to use ACEI/ARB or ARNI; 3. Cases without important effectiveness monitoring indicators (NT proBNP) and cases without important safety indicators (blood pressure, electrolyte, blood creatinine) before, after and during the 3-month follow-up period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality;Readmission rate of HF;NT-proBNP; | — |
Countries
China
Contacts
Public ContactLuo Min
West China Hospital of Sichuan Universty
Outcome results
None listed